Type I interferon underlies severe disease associated with Junín virus infection in mice

  1. Brady T Hickerson
  2. Eric J Sefing
  3. Kevin W Bailey
  4. Arnaud J Van Wettere
  5. Manuel L Penichet
  6. Brian B Gowen  Is a corresponding author
  1. Utah State University, United States
  2. University of California, Los Angeles, United States

Abstract

Junín virus (JUNV) is one of five New World mammarenaviruses (NWMs) that cause fatal hemorrhagic disease in humans and is the etiological agent of Argentine hemorrhagic fever (AHF). The pathogenesis underlying AHF is poorly understood; however, a prolonged, elevated interferon-a (IFN-a) response is associated with a negative disease outcome. A feature of all NWMs that cause viral hemorrhagic fever is the use of human transferrin receptor 1 (hTfR1) for cellular entry. Here, we show that mice expressing hTfR1 develop a lethal disease course marked by an increase in serum IFN-a concentration when challenged with JUNV. Further, we provide evidence that the type I IFN response is central to the development of severe JUNV disease in hTfR1 mice. Our findings identify TfR1-mediated entry and the type I IFN response as key factors in the pathogenesis of JUNV infection in mice.

Data availability

All data generated or analyzed during this study are included in the manuscript.

Article and author information

Author details

  1. Brady T Hickerson

    Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, United States
    Competing interests
    No competing interests declared.
  2. Eric J Sefing

    Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, United States
    Competing interests
    No competing interests declared.
  3. Kevin W Bailey

    Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, United States
    Competing interests
    No competing interests declared.
  4. Arnaud J Van Wettere

    Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, United States
    Competing interests
    No competing interests declared.
  5. Manuel L Penichet

    David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, United States
    Competing interests
    Manuel L Penichet, is a shareholder of Klyss Biotech, Inc. The Regents of the University of California licensed Dr. Penichet's technology to this firm. The author has no other competing interests to declare..
  6. Brian B Gowen

    Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, United States
    For correspondence
    brian.gowen@usu.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9113-2575

Funding

National Institutes of Health (R56 AI13646)

  • Brian B Gowen

National Institutes of Health (R01 AI14110)

  • Brian B Gowen

National Institutes of Health (R01 CA196266)

  • Manuel L Penichet

Utah State University (Graduate Research and Creative Opportunities grant)

  • Brady T Hickerson

The funders had no role in study design, data collection and interpretation or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal procedures complied with USDA guidelines and were conducted at the AAALAC-accredited laboratory animal research facilities at Utah State University under protocol #10034, approved by the Utah State University Institutional Animal Care and Use Committee.

Copyright

© 2020, Hickerson et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,371
    views
  • 153
    downloads
  • 11
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Brady T Hickerson
  2. Eric J Sefing
  3. Kevin W Bailey
  4. Arnaud J Van Wettere
  5. Manuel L Penichet
  6. Brian B Gowen
(2020)
Type I interferon underlies severe disease associated with Junín virus infection in mice
eLife 9:e55352.
https://doi.org/10.7554/eLife.55352

Share this article

https://doi.org/10.7554/eLife.55352

Further reading

    1. Epidemiology and Global Health
    2. Microbiology and Infectious Disease
    Gillian AM Tarr, Linda Chui ... Tim A McAllister
    Research Article

    Several areas of the world suffer a notably high incidence of Shiga toxin-producing Escherichia coli. To assess the impact of persistent cross-species transmission systems on the epidemiology of E. coli O157:H7 in Alberta, Canada, we sequenced and assembled E. coli O157:H7 isolates originating from collocated cattle and human populations, 2007–2015. We constructed a timed phylogeny using BEAST2 using a structured coalescent model. We then extended the tree with human isolates through 2019 to assess the long-term disease impact of locally persistent lineages. During 2007–2015, we estimated that 88.5% of human lineages arose from cattle lineages. We identified 11 persistent lineages local to Alberta, which were associated with 38.0% (95% CI 29.3%, 47.3%) of human isolates. During the later period, six locally persistent lineages continued to be associated with human illness, including 74.7% (95% CI 68.3%, 80.3%) of reported cases in 2018 and 2019. Our study identified multiple locally evolving lineages transmitted between cattle and humans persistently associated with E. coli O157:H7 illnesses for up to 13 y. Locally persistent lineages may be a principal cause of the high incidence of E. coli O157:H7 in locations such as Alberta and provide opportunities for focused control efforts.

    1. Microbiology and Infectious Disease
    Vandana Singh, Scot P Ouellette
    Research Article

    Chlamydia trachomatis is an obligate intracellular bacterial pathogen with a unique developmental cycle. It differentiates between two functional and morphological forms: the elementary body (EB) and the reticulate body (RB). The signals that trigger differentiation from one form to the other are unknown. EBs and RBs have distinctive characteristics that distinguish them, including their size, infectivity, proteome, and transcriptome. Intriguingly, they also differ in their overall redox status as EBs are oxidized and RBs are reduced. We hypothesize that alterations in redox may serve as a trigger for secondary differentiation. To test this, we examined the function of the primary antioxidant enzyme alkyl hydroperoxide reductase subunit C (AhpC), a well-known member of the peroxiredoxins family, in chlamydial growth and development. Based on our hypothesis, we predicted that altering the expression of ahpC would modulate chlamydial redox status and trigger earlier or delayed secondary differentiation. Therefore, we created ahpC overexpression and knockdown strains. During ahpC knockdown, ROS levels were elevated, and the bacteria were sensitive to a broad set of peroxide stresses. Interestingly, we observed increased expression of EB-associated genes and concurrent higher production of EBs at an earlier time in the developmental cycle, indicating earlier secondary differentiation occurs under elevated oxidation conditions. In contrast, overexpression of AhpC created a resistant phenotype against oxidizing agents and delayed secondary differentiation. Together, these results indicate that redox potential is a critical factor in developmental cycle progression. For the first time, our study provides a mechanism of chlamydial secondary differentiation dependent on redox status.